Summary
Amends the
Therapeutic Goods (Poisons Standard—February 2023) Instrument 2023
to amend the regulatory framework for medicinal cannabis by: re-scheduling medicinal cannabis, thereby allowing prescription by any medical practitioner; adopting a definition for cannabis as a regulated product that allows a higher level of tetrahydrocannabinol (THC); and allowing whole plant cannabis products with certain limits of THC and cannabidiol to be sold over the counter at a chemist or veterinary clinic to persons over 18 years of age.